Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Restylane Users for Wrinkles: Dermatologists

Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
November 19, 2007
CRx-191 - an intriguing combination product
Analysis of: CombinatoRx Announces Initiation of Phase 2a Clinical Study of CRx-191 in Psoriasis (www.pipelinereview.com)
CombinatoRx new combination product- CRx-191 is intriguing in that it combines a topical steroid with nortryptiline to minimize the negative effects of the steroid and make it more potent. This would be useful in that higher potency topical steroids are more effective, but cause more thinning of the...
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
November 12, 2007
Stifel and Allergan collaboration very positive
Analysis of: Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering (www.pipelinereview.com)
The recently announced collaboartion between Stiefel and Allergan in regards to Tazorac is very positive. Stiefel needs this molecule to put into different dosage forms, and in combination with its existing products espoecially Duac, etc. Their current acne product line is strong, but this will solodify...
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
October 8, 2007
Abbotts ABT-874 shows good results in Psoriasis
Analysis of: Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study (www.pipelinereview.com)
Abbotts ABT-874 monoclonal antibody for psoriasis shows impressive results in the phase 2 trial. The results were up to 90% of patients achieving at least 75% reduction in their psoriasis. These results are as good or better than those with Remicade the most effective biologic for psoriasis currently....
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
September 28, 2007
Relieva results in recent clinical trial for eczema
Analysis of: Relieva Exceeds Expectations In Recent Clinical Trial For Eczema (Atopic Dermatitis) (www.medicalnewstoday.com)
The recent results for a trial of Relieva in atopic dermatitis or eczema, a cream containing a homeopathic compound, were positive by a report from the company. The study sample was small, and the trial was open label. Generally these trials have a larger number of patients, and are blinded. Also it...
September 24, 2007
This treatment is unsafe and regulation is going to make it obsolete for a time
By a GLG Expert Contributor
Analysis of: Feel Pudgy? There’s a Shot for That (www.nytimes.com)
This treatment is run illegally, in violation of FDA laws Additionally, it is outlawed in Europe, Canada and Brazil, among other places Lastly, it isn't all that effective, from what I hear, and very painful.  In summary, better options will become available.
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology
Stanford University
September 10, 2007
FDA issues warning to Melanocorp
Analysis of: FDA Issues Warning Letter To Melanocorp, Inc. For Illegal Sale Of Melanotan II -Agency Warns Consumers About Using And Purchasing Unapproved Product (www.medicalnewstoday.com)
 The FDA warning to Melanocorp regarding their product Melanotan was justified. These warnings are far too few and infrequent, and numerous companies make claims without studies or substantiation. The agency is overwhelmed with NDA's, and has difficulty handling the work that currently exists....
Michael Bain, MD, Plastic and Reconstructive Physician
Michael A Bain, MD
August 28, 2007
This coud ne a Panora's Box
Analysis of: New Medicare Regulations Adopted To Reduce Certain Hospital Infections And Medical Errors (www.medicalnewstoday.com)
If a patient gets a bedsore, who pays for it? Most importantly, what does this mean to KCI and the other wound companies? Where will it end?
Michael Bain, MD, Plastic and Reconstructive Physician
Michael A Bain, MD
July 30, 2007
They have improved, but they are not the holy grail
Analysis of: Recurrence of Spider Angiomas After Laser Treatment (dermatology.jwatch.org)
Lasers are better than they were 10 years ago.  Especially for vascular lesions; however, they are not all purpose machines that can do everything, as evidenced by new ones every year.
July 19, 2007
Sculptra: proceed with caution
By a GLG Expert Contributor
Analysis of: Sculptra(TM), new cosmetic dermatology treatment, creates long-lasting, natural-looking results (www.newswire.ca)
I was trained on the use of New-fill in London about 5 years ago. My impression then was of a rather complicated to use product, compared to the existing fillers in the market like Hyaluronic Acid.
Michael Bain, MD, Plastic and Reconstructive Physician
Michael A Bain, MD
July 12, 2007
I would love it
Analysis of: Norwegian hacker says he can bypass AT&T on iPhone (today.reuters.com)
It would be great to get an unlocked i-phone...

Previous Page : 1 2 3 4 5 6 7 8 9 10 Next51 to 60 of 96

Analytics


Generated at 2009-01-09T13:00:20.343